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Abstract
Proteinases are involved in essential steps in cartilage and bone
homeostasis. Consequently, efforts have been made to establish
their potential role in the pathology of rheumatic conditions such as
rheumatoid arthritis, osteoarthritis and spondyloarthritis. Matrix
metalloproteinases (MMPs) are sensitive markers of disease
severity and response to treatment, and therefore they have poten-
tial in the assessment of rheumatic diseases. Despite disappointing
early results with synthetic inhibitors of MMPs, there is still much
scope for developing effective and safe MMPs inhibitors, and
consequently to deliver new options to inhibit joint destruction.
Introduction
Proteases are responsible for enzymatic cleavage of peptide
bonds [1,2], which is a basic requirement for completion of
diverse biological processes. Examples of contributions made
by proteases can be found in digestion, blood coagulation
and fibrinolysis. They are also involved in the processing of
precursors related to the synthesis of collagen, immune
functions, development and apoptosis [3]. The proteolytic
activity of proteases must be rigorously controlled to avoid
inappropriate degradation of proteins. Imbalance in regulation
of proteolytic activity can be found in a wide range of
diseases, including cancer, rheumatoid arthritis (RA) and
osteoarthritis (OA) [4].
Of particular importance is that proteases have been found to
play diverse and strategic roles in cartilage and bone
remodelling, which in recent years has engendered increased
interest in these enzymes in the field of rheumatology. To
highlight the clinical relevance of proteinases to joint
destruction, we discuss their contribution to cartilage and
bone homeostasis in health and give particular emphasis to
their crucial role in diseases such as RA, OA and
spondyloarthritis.
General features of proteinases
Proteases selectively hydrolyze a peptide bond in a poly-
peptide chain of a target molecule. Depending on the
position of the peptide bond, proteases are referred to as
exopeptidases or endopeptidases. Exopeptidases specifically
cleave substrates at the amino-terminal or carboxyl-terminal
positions of polypeptides, and therefore can be subdivided
into aminopeptidases and carboxypeptidases [5,6]. Endo-
peptidases (also called proteinases) break peptide bonds in
the middle of the molecule. They can be subclassified based
on their mechanism of catalysis, which is related to the
chemical group involved in the process of hydrolysis. As a
consequence, endopeptidases are described as aspartate,
cysteine and threonine types, which act intracellularly in an
acid pH, or as serine and metallo catalytic types, which act
extracellularly in a neutral pH environment [6]. Each of these
catalytic types is described in the following discussion (a
summary is provided in Figure 1).
Aspartate proteinases
A well known representative aspartic proteinase is cathepsin
D. The major function of cathepsin D is to digest proteins and
peptides within the acidic compartment of the lysosome [7]. It
apparently is also involved in the processing of hormones,
neuropeptides and antigens [7-9]. Therefore, cathepsin D
has been proposed to be a potential target that could allow
modulation of autoimmune diseases [8].
Cysteine proteinases
Cysteine proteinases are generally known as cathepsins
(types B, K, L, S, H, F, C, X and O) [10]. Cathepsin S is the
major processing enzyme of the major histocompatibility
complex class II invariant chain. Cathepsins L and F partici-
pate in the same process, primarily in tissues or cells that do
not express cathepsin S. Finally, cathepsin K was found to be
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crucial in bone remodelling and is predominantly expressed in
osteoclasts. Interestingly, it has also been described in
synovial fibroblasts and macrophages of RA joints [11].
Threonine proteinases
This class of proteinases represents a crucial element in the
proteosome. Along with lysosomal proteolysis, the ubiquitin-
proteosome pathway is the main intracellular cascade for
controlled degradation of proteins [12]. It plays an important
role in a variety of fundamental cellular processes, including
cell cycle progression, cell division, development, differen-
tiation and apoptosis. Furthermore, it influences cell traffick-
ing and modulates immune and inflammatory responses [13].
Serine proteinases
This is a family of enzymes that contain a serine residue in
their active site [14]. They are of particular interest because
they have been implicated in a variety of physiological and
pathological processes. For example, the urokinase-type
plasminogen activator (uPA) and tissue-type plasminogen
activator play a critical role in several processes, including
clot dissolution, extracellular matrix (ECM) remodelling, angio-
genesis and wound healing, as well as tumour invasion and
metastasis [15]. uPA converts plasminogen to plasmin, which
is a broad-spectrum enzyme that can degrade not only fibrin
but also proteins of the joint ECM and cartilage. By single
proteolytic cleavage, both uPA and plasmin produce active
forms of matrix metalloproteinases (MMPs) [16].
Metalloproteinases
This group of proteases is divided into five families: the
serralysins, the astacins, the adamalysins, the MMPs and the
pappalysins [5]. The family of MMPs is best known for its
ability to cleave components of the ECM, but they also cleave
Figure 1
Summary of proteases. MMP, matrix metalloproteinase; MT, membrane-type; tPA, tissue-type plasminogen activator; uPA, urokinase-type
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(page number not for citation purposes)
other proteinases and proteinase inhibitors, latent growth
factors and growth factor binding proteins, chemotactic
molecules, cell surface receptors and cell-cell adhesion
molecules. MMPs regulate many biological processes and
consequently they are precisely controlled at various critical
steps, including synthesis and secretion, activation of pro-
enzymes and inhibition of active enzymes. However, the locali-
zation and clearance of MMPs is also tightly controlled [17].
Matrix metalloproteinases and adamalysins:
key characteristics
The MMPs and adamalysins are considered to be major
mediators of cartilage destruction in arthritic diseases and
have attracted particular research interest.
Matrix metalloproteinases
In general, MMPs are composed of three distinct domains
[18]: a pre-domain, which is required for enzyme maturation
and release from the cell; a prodomain, which maintains the
enzyme in an inactive state; and the catalytic domain, which
characteristically contains a zinc atom and is responsible for
enzyme activity. Because of their rather diverse structures
and biological functions, they are classified into at least five
main groups (Figure 1) according to their substrate speci-
ficity, primary structure and cellular localization (Table 1):
collagenases, gelatinases, stromelysins, the matrilysins and
membrane-type (MT) MMPs. Apart from those included in
these main groups, other MMPs have been described
including MMP-12 (metalloelastase), MMP-19, MMP-20
(enamelysin), MMP-20 and MMP-23, as well as XMMP
(Xenopus) and CMMP (chicken) [19] (for review, see [20]).
As mentioned above, various mechanisms are involved in the
regulation of MMPs [18], including transcription control, pro-
enzyme activation, and inhibition of active enzymes by natural
inhibitors. MMP gene expression is regulated at the
transcriptional level, controlled by the stimulating effects of
cytokines (such as IL-1β and tumour necrosis factor [TNF]-α)
and growth factors (such as epidermal growth factor, platelet-
derived growth factor, basic fibroblast growth factor and
transforming growth factor-β). After binding to their
membrane receptor these cytokines and growth factor
generate a signalling cascade, which involves activator
protein-1 (AP-1) transcription factors and finally leads to the
transcription of MMPs [21].
The production of MMPs as pro-enzymes is another important
mechanism of regulation. They are produced as inactive
forms and require further cleavage by other proteinases to
become active. MMPs can be activated by MT1-MMP, MT2-
MMP and MT5-MMP [19], or by plasmin, uPA and tissue-type
plasminogen activator [21]. The initial proteolytic activation of
MMPs occurs at an exposed region of the pro-domain. First,
the pro-domain is removed, which leads to destabilization of
the molecule. The next step includes participation of the
cysteine switch-zinc mechanism [22]. This mechanism
involves the dissociation of a cysteine residue from the zinc
atom in the catalytic domain to expose the active site. Finally,
the active form can be autocatalytically cleaved by the
activated metalloprotease [21].
MMPs are also regulated by tissue inhibitors of metallo-
proteinases (TIMPs) [19]. TIMPs are produced by the same
cells that produce the MMPs and bind to them at a ratio of
1:1 in order to induce their inactivation. Changes in levels of
TIMPs are particularly important because they directly affect
MMP activity [22]. Thus far, four TIMPS have been described;
TIMP-1, TIMP-2 and TIMP-4 are present in soluble forms
[23], whereas TIMP-3 is tightly attached to the matrix by
binding to proteoglycans [24].
Adamalysins
ADAM
The adamalysin family includes the adamalysins (ADAM [a
disintegrin and metalloproteinase]) and ADAMTS (a disintegrin
and metalloproteinase with thrombospondin motif). There are
more than 30 members of the ADAM family, with a prominent
sheddase activity described. Sheddases proteolytically
cleave cellular membrane proteins by detachment of their
extracellular region [25]. Most relevant to bone and cartilage
remodelling is ADAM-17, because it sheds TNF-α and TNF-α
receptors from the membrane. After the shedding and
releasing of TNF-α, it can function in a paracrine and
endocrine manner [25].
ADAMTS
Aggrecanases are the main proteinases responsible for
aggrecan cleavage in the early events of cartilage remodel-
ling. Later, MMPs participate in this process and continue
with the degradation of collagen [26]. In the cartilage, two
different aggrecanases have been isolated, aggrecanase-1
(ADAMTS-4) and aggrecanase-2 (ADAMTS-5) [26]. Like all
metalloproteinases, both ADAMTS-4 and ADAMTS-5 rely on
the cysteine switch mechanism for activation. In addition, they
can be activated by furin-like proprotein convertases [27,28].
Like MMPs, ADAMTS-4 and ADAMTS-5 are inhibited by
TIMP-3 [29].
Proteinases in the joint
It is generally accepted that proteolytic enzymes are involved
in the catabolic aspect of normal tissue remodelling and that
altered activity of these enzymes is responsible for the
cartilage destruction and bone erosion associated with
disorders such as OA and RA [30].
Articular cartilage in adults is a comparatively acellular tissue,
with a cell volume approximating 2% of the total cartilage
volume. The remainder is occupied by an extensive ECM [31].
The structural backbone of this matrix is the collagen fibril.
Articular cartilage is mainly composed by type II collagen, but
it also contains types IX and XI collagen, both on the surface
and within. Many other matrix molecules are found in
Available online http://arthritis-research.com/content/9/5/221association with the collagen fibrils, the most common and
largest of which is the large proteoglycan aggrecan. It forms
molecular aggregates with hyaluronic acid, which in turn
interacts with the collagen fibrillar network [32]. Further
elements of the cartilage matrix are leucine-rich proteoglycans,
including decorin, fibromodulin and biglycan [32].
Cartilage and bone turnover is a complex process in which
proteinases play a prominent role in health and disease. The
cartilage remodelling process is conducted entirely by a
single cell type, namely the chondrocyte. This cell is not only
responsible for the synthesis of the complex ECM of the
articular cartilage, but it is also the source of proteinases and
other mediators that degrade the damaged matrix to permit
repair [33]. The production of these proteolytic enzymes is
regulated by various local mediators, such as cytokines,
growth factors, prostaglandins, matrix breakdown products,
complement, oxygen species and neuropeptides [34].
Similar to cartilage, the bone tissue undergoes continuous
remodelling. Osteoclasts play a prominent role in the
resorption of bone in this remodelling cycle. By secreting H+
ions and proteinases, osteoclasts dissolve bone mineral and
degrade organic bone matrix [35]. Osteoclast-mediated bone
resorption is a multistep process that is initiated by the
attachment of osteoclasts to the bone surface. After they
have attached to the bone surface, a tightly sealed resorption
lacuna is created. Then proteolytic enzymes expressed in
osteoclasts, such as cathepsin K and MMPs (MMP-13,
MMP-2 and MMP-9), are secreted into the lacuna for removal
of bone mineral and degradation of organic matrix protein
[32]. MMPs are essential for the initiation of the osteoclastic
resorption process by removing the collagenous layer from
the bone surface, which must be achieved before the
demineralization process can be initiated. MMPs have also
been implicated in the cleansing of bone lining cells from
resorption pits of remaining collagen fibrils before the pits are
refilled with new bone matrix components produced by
osteoblasts [11]. Additionally, MMP-12 produced by
osteoclasts or periosteoclastic cells contributes to bone
matrix solubilization and osteoclast migration, thereby
controlling the cell-matrix interactions that are required for cell
attachment/detachment [36]. In summary, proteinases
participate importantly in normal bone and cartilage turnover,
whereas deregulation of proteinases is relevant to several
joint diseases.
Proteinases in the diseased joint
The cellular and molecular mechanisms that underlie patho-
logical bone destruction have partially been identified. In
particular, molecular insight into osteoclast biology has
revealed that even though inflammation and destruction are
independent processes, they are linked to each other [30].
The link is established through the network of cytokines and
growth factors that are produced by cells in the inflamed joint
[35]. Proinflammatory cytokines such as TNF-α and IL-1 are
abundant in the synovium of patients with various types of
chronic arthritis, and they disrupt normal tissue homeostasis
in cartilage and bone [30]. The influence of cytokines in
osteoclast differentiation provides a link between inflam-
mation and the process of bone destruction. Some cytokines
such as IL-1 directly induce osteoclast differentiation, where-
as others such as TNF-α act indirectly by upregulating
RANKL (receptor activator of nuclear factor-κB ligand), which
is the major factor involved in osteoclast differentiation and
activation [37].
One of the strongest predictors of long-term outcome in RA
and OA is progressive joint damage. In RA and OA, this
progressive cartilage and bone destruction are considered to
be driven by excess MMP enzymes [38]. The profile of MMPs
expressed by activated cells in arthritic joints is sufficient to
destroy completely the structural collagens that build up the
articular cartilage, the adjacent bones and tendons, as well as
the noncollagen matrix molecules [7].
Proteinases in rheumatoid arthritis
In RA functional disability is a multifactorial process, and
damage to the joint structures contributes significantly to the
overall functional status of the patient [31]. Degradation of
the cartilage, tendon and bone ECM proteins by MMPs is the
hallmark of synovial joint destruction [39]. In this process loss
of aggrecans, considered a critical event in arthritis, initially
occurs at the surface of the cartilage and then progresses to
deeper zones. This is followed by degradation of collagen
fibrils and mechanical failure of the tissue [39].
There are two principal mechanisms by which RA synovial
tissue contributes to loss of cartilage. The first and direct
mechanism involves the production of MMPs and cathepsins
by the RA synovium [33]. The second mechanism indirectly
induces cartilage remodelling by deregulation of chondrocyte
function through the release of cytokines and other mediators
from the synovium [33]. As part of the inflammatory process
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Table 1
The five main groups of matrix metalloproteinases
Group MMPs
Collagenases MMP-1 (collagenase-1), MMP-8 (collagenase-2), 
MMP-13 (collagenase-3), 
MMP-18 (collagenase-4)
Gelatinases MMP-2 (gelatinases A), MMP-9 (gelatinases B)
Stromelysins MMP-3 (stromelysin-1), MMP-10 (stromelysin-2), 
MMP-11 (stromelysin-3)
Matrilysins MMP-7, MMP-26
MT MMPs MMP-14 (MT1-MMP), MMP-15 (MT2-MMP), 
MMP-16 (MT3-MMP), MMP-17 (MT4-MMP), 
MMP-24 (MT5-MMP), MMP-25 (MT6-MMP)
MMP, matrix metalloproteinase; MT, membrane type.in RA, macrophages are recruited to the joints, where they
release inflammatory cytokines such as IL-1β, TNF-α and IL-6.
These cytokines induce expression of proteinases in synovial
fibroblasts and chondrocytes [40].
It has been demonstrated that synovial cells stimulated by
TNF-α or IL-1β increase the transcription of cathepsin B
[40-42]. The location of cathepsin B appeared to be
restricted to synovial cells attached to cartilage and bone at
sites of RA joint erosion [43]. Accumulation of active
cathepsin B in the synovial fluid of RA patients is probably
related to destruction of subchondral bone [44]. Interestingly,
cathepsin B, along with MMP-1 and cathepsin L, has been
detected in the synovium soon after onset of symptoms,
implying that the potential for joint destruction exists even at
very early stages of the disease [45,46].
Also, cathepsin K is highly expressed in synovial fibroblasts
and macrophages in joints of RA patients [11,47,48]. In
addition to its major role in bone resorption, it has been
demonstrated that cathepsin K plays a critical role in
cartilage degradation as well. Co-cultures of synovial
fibroblasts on cartilage disks revealed the ability of fibro-
blasts to phagocytose collagen fibrils [49]. This degenera-
tive property of fibroblasts was prevented by a potent
cathepsin K inhibitor.
The important role of MMPs in cartilage and bone destruction
in RA has been demonstrated using various approaches.
High levels of MMP-1, MMP-3, MMP-8 and MMP-9 are found
in the synovial fluid of patients with RA [50]. Moreover, the
synovial tissue exhibits high constitutive expression of
MMP-2, MMP-11 and MMP-19 [51]. The expression of
MMP-3 is particularly high in synovial tissue from RA patients,
suggesting that MMP-3 plays a significant role in the
progression of erosions of the cartilage [52]. Interestingly, a
high MMP/TIMP ratio was identified in the serum of RA
patients [52], implying an imbalance in the proteolytic system
in favour of the MMPs.
Finally, it has been shown that RA synovial fibroblasts exhibit
increased production of MMPs (MMP-1, MMP-3, MMP-13,
MMP-14 and MMP-15) and contribute significantly to the
joint destruction observed in RA [53,54]. This high expres-
sion of MMPs by RA synovial fibroblasts is not only
upregulated by elevated levels of IL-1β and TNF-α [40] but is
also sustained intrinsically by RA synovial fibroblasts, which
display a transformed phenotype [55].
In summary, the inflammatory environment observed in the
synovial tissue allows the production and secretion of
cytokines and growth factors by infiltrating cells and resident
synovial cells. This leads to increased production of
ADAMTSs and MMPs by synovial fibroblasts and by
chondrocytes, favouring cartilage and bone destruction
(Figure 2b).
Because of the significant roles played by MMPs in joint
destruction, they have been regarded as useful biomarkers
and therapeutic targets. Levels of MMP-1 and MMP-3 in the
serum of RA patients correlate with disease activity [56]. For
that reason, it has been suggested that MMP-3 could be a
useful marker for predicting of bone and cartilage damage in
early untreated RA [57]. Successful treatment with
leflunomide [58], methotrexate [53], or anti-TNF-α antibodies
efficiently downregulates serum levels of MMPs [59,60].
Although these recent advances in RA treatment arrest
radiological joint destruction for some time, none of the
disease-modifying antirheumatic dugs, including the
biological agents, have yet provided long-term, problem-free
protection against joint destruction [54]. Therefore, there
remains a need to develop novel therapeutic strategies.
Proteinases in osteoarthritis
The aetiology of OA is not completely understood, but it
appears to result from mechanical, biochemical and enzy-
matic factors. The final common pathway of these inter-
actions is the failure of the chondrocytes to maintain a
homeostatic balance between matrix synthesis and degrada-
tion [19,61]. Therefore, excessive digestion of cartilage
collagen is considered a critical issue in loss of articular
cartilage in OA [62]. However, the chondrocytes not only
secrete the proteinases responsible of cartilage destruction,
but they also produce proinflammatory cytokines such as IL-1
and TNF-α, creating an inflammatory environment that also
favours increased synthesis of proteinases [17] (Figure 2a).
The destruction of the ECM in OA results from several events
that take place in sequence. The first critical step is loss of
cartilage aggrecans mediated by ADAMTS-4 and
ADAMTS-5. Then, diverse MMPs continue to degrade the
major components of the ECM [63]. Secondary cartilage
breakdown products, such as fibronectin fragments, are
released into the joint fluid and irritate the synovial membrane
lining in the joint space. The resulting synovitis provokes
release of inflammatory mediators from synovial tissue and
initiates recruitment of mononuclear inflammatory cells into
the joint space. These arriving cells secrete IL-1 and TNF-α,
which further upregulate the production of proteinases by
chondrocytes and synovial fibroblasts [64,65] (Figure 2).
In OA, expression of MMPs, ADAMTS and TIMPs exhibits a
particular pattern [66]. The coexistence of multiple collagena-
ses, plus their distinct localization and distribution in the
cartilage, points to a specific role for each of them. For
example, it is proposed that MMP-1 is involved in tissue
destruction initiated in the superficial zone of the cartilage
during inflammation, whereas MMP-13 plays a role in the
remodelling phase of the disease [19]. Furthermore, it has
been shown that MMP-2 and MMP-9 are increased in OA
joints and that their expression is enhanced by IL-1 and
TNF-α [19]. In OA, TIMPs do not increase to the same extent
as proteinases do, producing a disproportionate ratio of MMP
Available online http://arthritis-research.com/content/9/5/221
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aggravates cartilage breakdown and promotes joint destruc-
tion [66,67].
Proteinases in spondyloarthritis
The spondyloarthropathies (SpAs) represent a group of
related arthritides that include ankylosing spondylitis,
psoriatic arthritis, reactive arthritis, and enteropathic and un-
differentiated SpA. They are characterized by their
association with HLA-B27 and development of sacroilitis and
enthesitis. The observed functional impairment, disability and
impaired quality of life resemble those in RA [68].
MMPs and TIMPs are expressed in the synovial compartment
of SpA patients [67]. In particular, high expression of MMP-3
has been demonstrated in serum, synovial tissue and synovial
fluids of SpA patients [69,70]. TNF-α blockade can induce a
downregulation of MMPs and TIMPs in the synovium of
affected joints and decreases levels of MMP-3 in the serum
[70]. Consequently, some authors have predicted a possible
role for MMPs as biomarkers of disease activity or response
to treatment [71].
Most recently, our group showed that new small erosions
appear in the bony processes of the vertebrae even in late
stages of the disease (at the time of surgical correction), and
that these sites of destruction appear to be caused by
osteoclasts producing MMPs, in particular cathepsin K [72].
These findings might explain why patients still experience
significant pain at late stages of the disease.
Proteinases as therapeutic targets
Because of the prominent roles of metalloproteinases
observed in degenerative diseases, they are attractive as
Arthritis Research & Therapy    Vol 9 No 5 Rengel et al.
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Figure 2
Proteinases in joint destruction. Shown are the proteinases that are involved in the joint destruction that occurs in (a) osteoarthritis and 
(b) rheumatoid arthritis. ADAM, a disintegrin and metalloproteinase-like; ADAMTS, ADAM-thrombospondin; IL, interleukin; MMP, matrix
metalloproteinase; MT, membrane-type; RANKL, receptor activator of nuclear factor-κB ligand; TNF, tumour necrosis factor; tPA, tissue-type
plasminogen activator; uPA, urokinase-type plasminogen activator.therapeutic targets. Several approaches to block the
deleterious effects of proteinases in pathological conditions
have been evaluated. These approaches include use of
synthetic metalloproteinase inhibitors, inhibition of signal
transduction pathways and gene transfer technology.
Synthetic metalloproteinase inhibitors
The synthetic inhibitors of MMPs can be divided into three
pharmacological categories [73]: collagen peptidomimetics
and nonpeptidomimetics; tetracycline derivatives; and
bisphosphonates.
Collagen peptidomimetics and nonpeptidomimetics
Peptidomimetic MMP inhibitors are pseudopeptide deriva-
tives that have been synthesized to mimic the structure of
collagen at the site where MMPs bind to cleave it. The
compounds batismastat and marismastat are examples of
peptidomimetic MMP inhibitors [73,74]. The clinical
development of batismastat was hampered by poor oral bio-
availability and solubility [75]. The preclinical studies of
marimastat have demonstrated inhibition of progression of
lung and breast tumours. However, several published clinical
trials have been unable to demonstrate benefit from using
marimastat as a single agent in diverse cancers. Neverthe-
less, the combination of marimastat with other chemo-
therapeutic agents has proven to be well tolerated and to
have synergistic action in inhibiting tumour growth [75].
Prinomastat, BMS-275291 and BAY 12-9566 (tanomastat)
are examples of nonpeptidomimetic inhibitors. Their use in
cancer therapy has been disappointing. Prinomastat failed to
improve the outcome in advanced non-small-cell lung cancer
[76]. A clinical trial of prinomastat in patients with
adenocarcinoma of the oesophagus required early closure
because of unexpected thromboembolic events [77]. Also,
BMS-275291 increases toxicity to chemotherapy and does
not improve survival in advanced non-small-cell lung cancer
[78]. Finally, BAY 12-9566 was well tolerated but there was
no evidence of an impact on outcome in patients with
advanced ovarian cancer [79].
With regard to joint diseases, Ro 32-3555 protected
cartilage from degradative changes in a mouse model of OA
[80] and it was well tolerated in a trial including RA patients
[81]. In general, peptidomimetic and nonpeptidomimetic
metalloproteinase inhibitors have been tested in bone
diseases but, although they inhibited bone destruction in
animal models, they failed to confer benefit in human trials.
Tetracycline derivatives
Use of tetracycline derivatives is another possible therapeutic
strategy. They can inhibit the activity and production of MMPs
(MMP-1, MMP-3 and MMP-13, and MMP-2 and MMP-9).
This family of agents includes tetracycline, doxycycline,
minocycline and the tetracycline analogues that have been
chemically modified to eliminate their antimicrobial activity.
Some of these tetracycline derivatives have been evaluated in
preclinical cancer models and have entered early clinical trials
in patients with malignant diseases [73]. Thus far, doxycycline
has been effective in reducing the rate of joint-space
narrowing in patients with established knee OA [82].
Bisphosphonates
Published data regarding the role of bisphosphonates as
MMPs inhibitors include those from preclinical studies only.
These agents inhibited transforming growth factor-β1 induced
MMP-2 secretion in PC-3 prostate cancer cell lines.
Clodronate also inhibited the expression of the MT1-MMP
protein and mRNA in the HT1080 fibrosarcoma cell line, and
decreased the invasion of C8161 melanoma and HT1080
fibrosarcoma cell lines [73].
Inhibition of signal transduction pathways
The development of selective protein kinase inhibitors that
can block or modulate diseases caused by abnormalities in
these signalling pathways is widely considered a promising
approach to drug development [22]. The signal transduction
pathways activated when IL-1β and TNF-α bind to their
cognate receptors on synovial cells and chondrocytes are
potential drug targets. Chemical blockade of mitogen-
activated protein kinase pathways inhibits expression of MMP
genes in tissue culture experiments and blocks the
progression of arthritis in animal models. SB203580, a p38
mitogen-activated protein kinase inhibitor, blocks both
MMP-13 gene expression in cultured chondrocytes and IL-1
mediated collagen degradation in cartilage explants.
However, further clinical research is needed [17].
Gene transfer
Gene transfer technology has also been applied to treatment
of RA. A transgene is a gene that is artificially introduced into
an organism or cell to modify their genome and function [83].
Gene transfer improves the delivery of therapeutic proteins
and allows stable and high concentrations of therapeutic
peptides to be achieved [83]. Gene transfer studies in the
severe combined immunodeficient mouse model of cartilage
invasion made it possible to evaluate selective inhibition of
specific enzymes and their individual contributions to joint
destruction. In this regard, inhibition of cathepsin L by a
specific ribozyme was able to reduce expression of cathepsin
L mRNA to 44% [84]. A ribozyme was also utilized to target
MMP-1 in the same model [85]. In other work, an anti-sense
construct against MT1-MMP was designed and transferred
into RA synovial fibroblasts for studies in the severe
combined immunodeficient mouse model [84], but invasive-
ness of RA synovial fibroblasts into the co-transplanted
cartilage could only be moderately reduced. Similarly, transfer
of a cell surface targeted plasmin inhibitor was not as
effective in vivo as it was in vitro [86]. In contrast, transferring
TIMPs into RA synovial fibroblasts has resulted in a remarked
inhibition of RA synovial fibroblast mediated cartilage
destruction [87]. Because TIMP-3, for instance, both inhibits
Available online http://arthritis-research.com/content/9/5/221
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shedding of TNF-α converting enzyme and IL-6, therapeutic
application of a TIMP-3-like molecule could potentially
prevent both the cytokine-driven activation of synovial cells
and cytokine-independent activation of RA synovial
fibroblasts [87].
Conclusion
Tight control of proteinases in the joints allows the integrity of
the bone and cartilage to be conserved. Failure to regulate
the synthesis, activation and inhibition of the proteinases
favours the deleterious effects of MMPs, including MMP-1,
MMP-3 and others, which finally lead to degradation. Despite
early disappointing results with synthetic inhibitors of MMPs
in human trials, there remains much scope for developing
effective but highly selective and safe MMP inhibitors. This
novel group of drugs could provide new therapeutic options
to inhibit joint destruction, which is the main reason for the
disability observed in RA, OA and the SpAs.
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